MB-105 in Patients With CD5 Positive T-cell Lymphoma (NCT06534060)
A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).
🩺 Plain-English Summary (8th-Grade Level)
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Who can join: Review the eligibility criteria below.
Location: University of San Diego (UCSD)-Moores Cancer Center — San Diego, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- University of San Diego (UCSD)-Moores Cancer Center — San Diego, California
- SCRI - Colorado Blood Cancer Institute (CBCI) — Denver, Colorado
- Moffitt Cancer Center Magnolia Campus — Tampa, Florida
- University of Iowa — Iowa City, Iowa
- Massachusetts General Hospital — Boston, Massachusetts
- University of Nebraska — Omaha, Nebraska
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Oregan Health & Science University — Portland, Oregon
- Baylor College of Medicine — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (713) 898-0838
Email: clinicaltrials@march.bio
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, T-Cell
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma — Charlottesville, Virginia
Explore by condition: All Lymphoma, T-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.